WAVE Life Sciences Ltd. $WVE Stock Position Raised by Knott David M Jr

Knott David M Jr boosted its position in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) by 125.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 90,000 shares of the company’s stock after purchasing an additional 50,000 shares during the period. Knott David M Jr’s holdings in WAVE Life Sciences were worth $659,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in WVE. Federated Hermes Inc. raised its stake in WAVE Life Sciences by 678,144.7% during the 3rd quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock valued at $27,455,000 after purchasing an additional 3,750,140 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in shares of WAVE Life Sciences by 20.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock worth $97,607,000 after buying an additional 2,500,000 shares during the period. Loomis Sayles & Co. L P grew its holdings in shares of WAVE Life Sciences by 35.3% during the second quarter. Loomis Sayles & Co. L P now owns 3,295,700 shares of the company’s stock valued at $21,422,000 after buying an additional 859,160 shares in the last quarter. Stempoint Capital LP grew its holdings in shares of WAVE Life Sciences by 902.2% during the second quarter. Stempoint Capital LP now owns 900,338 shares of the company’s stock valued at $5,852,000 after buying an additional 810,505 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in WAVE Life Sciences by 33.1% during the second quarter. JPMorgan Chase & Co. now owns 1,569,015 shares of the company’s stock valued at $10,199,000 after buying an additional 390,078 shares during the period. 89.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on WVE shares. Oppenheimer increased their price objective on WAVE Life Sciences from $24.00 to $32.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Royal Bank Of Canada upgraded WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $9.00 to $27.00 in a report on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Wednesday, January 21st. Wells Fargo & Company decreased their price target on shares of WAVE Life Sciences from $29.00 to $27.00 and set an “overweight” rating for the company in a report on Thursday, February 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of WAVE Life Sciences in a research report on Monday, March 2nd. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, WAVE Life Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $33.13.

Insider Transactions at WAVE Life Sciences

In other WAVE Life Sciences news, CFO Kyle Moran sold 210,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $14.77, for a total value of $3,101,700.00. Following the completion of the sale, the chief financial officer directly owned 89,218 shares of the company’s stock, valued at $1,317,749.86. The trade was a 70.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Adrian Rawcliffe sold 42,000 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $15.00, for a total transaction of $630,000.00. Following the transaction, the director owned 12,700 shares in the company, valued at approximately $190,500. This trade represents a 76.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 948,375 shares of company stock valued at $14,112,151 in the last ninety days. 23.98% of the stock is currently owned by insiders.

Trending Headlines about WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Wedbush raised its price target on WVE to $35 and reiterated an “outperform” rating — a bullish signal implying substantial upside versus the current price and likely supporting buy-side interest. Wedbush price target raise
• Positive Sentiment: HC Wainwright increased near-term EPS estimates across Q1–Q4 2026 and kept a “Buy” rating with a $30 target, signaling improving analyst sentiment on WAVE’s financial outlook. (Research note summarized in market coverage.)
• Positive Sentiment: Wave announced acceptance of a late‑breaking oral presentation for WVE‑006 (GalNAc‑RNA editing) at the American Thoracic Society conference — new data from the RestorAATion‑2 trial (400 mg multidose and 600 mg single‑dose cohorts) will be presented, which could materially move the stock depending on the clinical readout. ATS presentation acceptance
• Neutral Sentiment: Analysts’ long‑range earnings expectations were updated in a report setting FY2029 estimates — useful for modeling but unlikely to drive immediate price moves absent near‑term catalysts. Analyst expectations for FY2029
• Negative Sentiment: A CNBC piece highlighted recent FDA reversals and heightened regulatory scrutiny across biotech (citing multiple denials and reversals), which has increased sector volatility and likely weighed on WVE shares despite company‑specific positives — investors are more sensitive to regulatory risk today. FDA reversals raise sector concerns

WAVE Life Sciences Price Performance

Shares of NASDAQ WVE opened at $13.12 on Friday. WAVE Life Sciences Ltd. has a one year low of $5.28 and a one year high of $21.73. The business’s 50-day moving average price is $14.00 and its two-hundred day moving average price is $10.94. The company has a market capitalization of $2.47 billion, a P/E ratio of -10.75 and a beta of -1.77.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). The firm had revenue of $17.25 million for the quarter, compared to analysts’ expectations of $15.68 million. WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%. On average, equities analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 EPS for the current year.

WAVE Life Sciences Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.